Volagidemab
As of the edition of 20 October 2026, Volagidemab is an antibody: in active development; acts on GCGR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Antibody
- Registered trials
- 10, 2 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Immune system; Cancer; Blood and lymph; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GCGR | Glucagon receptor | P47871 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 3 | 1 | 2 |
| Phase 2 | 4 | 3 | 1 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| REMD Biotherapeutics | Lead sponsor of trials | 2015 to now |